Too often, people promote remedies for irritable bowel syndrome that have little to no scientific backing.

Q: I was diagnosed with IBS and feel like that basically means no one knows what’s going on. I’ve seen people recommend ...

Good afternoon, and welcome to Bausch Health's First Quarter 2026 Earnings Conference Call. My name is Garen Sarafian, Vice President of Investor Relations. Participating in today's call are Thomas ...

Detailed price information for Bausch Health Companies Inc (BHC-N) from The Globe and Mail including charting and trades.

Q1 2026 Management View CEO Thomas Appio said, “We began 2026 with another strong performance,” and highlighted “12 consecutive quarters of year-over-year growth in both revenue and adjusted EBITDA ...

In a new study published in Clinical Gastroenterology and Hepatology, the low FODMAP diet and the antibiotic rifaximin provided similar and significant relief for patients with irritable bowel ...

In a new study published in Clinical Gastroenterology and Hepatology, the low FODMAP diet and the antibiotic rifaximin provided similar and significant relief for patients with irritable bowel ...

In a new study published in Clinical Gastroenterology and Hepatology, the low FODMAP diet and the antibiotic rifaximin provided similar and significant relief for patients with irritable bowel ...

Cholestyramine/colestipol, eluxadoline, and rifaximin were not associated with mortality for IBS-D, but an increased mortality risk was seen for diphenoxylate and ...

A huge study found a link between some medications – especially antidepressants and anti-diarrheal drugs – and an increased ...

News and commentary from the world of gastroenterology and hepatology ...